FindTrial
Sign In

Crinecerfont

DRUG5 trials

Sponsors

Neurocrine Biosciences, Neurocrine Switzerland GmbH

Conditions

CAH - Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia

Phase 2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
CompletedNCT04045145
Neurocrine BiosciencesCAH - Congenital Adrenal Hyperplasia
Start: 2019-12-12End: 2021-07-02Updated: 2024-07-18
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Active, not recruitingNCT07187375
Neurocrine Switzerland GmbHCongenital Adrenal Hyperplasia
Start: 2025-09-30End: 2029-10-04Updated: 2026-08-28
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
RecruitingNCT07536269
Neurocrine Switzerland GmbHCongenital Adrenal Hyperplasia
Start: 2026-07-01End: 2028-03-01Target: 20Updated: 2026-09-16

Phase 3

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Active, not recruitingNCT04490915
Neurocrine BiosciencesCongenital Adrenal Hyperplasia
Start: 2020-12-16End: 2027-08-01Updated: 2026-05-11
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Active, not recruitingNCT04806451
Neurocrine BiosciencesCongenital Adrenal Hyperplasia
Start: 2021-06-25End: 2027-08-31Updated: 2025-02-05

Related Papers

SUN-441 Crinecerfont Shows Favorable Trends in Improving Clinical Outcomes in Children and Adolescents With Classic Congenital Adrenal Hyperplasia: 1-Year Results From the CAHtalyst™ Pediatric Study
Journal of the Endocrine Society2025-10-01
OR07-05 Crinecerfont Maintains Reductions in Serum Androstenedione Levels and Glucocorticoid Doses in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 1-Year Results from the CAHtalystTM Pediatric Study
Journal of the Endocrine Society2025-10-01
OR07-04 Crinecerfont Allows for More Physiologic Glucocorticoid Treatment With Reduction of Androstenedione to a Normal Range in Adults With Classic Congenital Adrenal Hyperplasia: Post Hoc Analyses of the CAHtalyst™ Adult Study
Journal of the Endocrine Society2025-10-01
SUN-434 Crinecerfont Reduces Plasma Adrenocorticotropic Hormone and Serum 17-Hydroxyprogesterone Levels in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 1-Year Results from the CAHtalystTM Pediatric Study
Journal of the Endocrine Society2025-10-01
SUN-405 Crinecerfont Shows Favorable Trends in Improving Weight-Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia: 1-Year Results From the CAHtalyst™ Adult Study
Journal of the Endocrine Society2025-10-01
MON-459 Crinecerfont Shows Favorable Trends in Improving Weight-Related Outcomes in Pediatric Patients With Classic Congenital Adrenal Hyperplasia: 1-Year Results from the CAHtalyst™ Pediatric Study
Journal of the Endocrine Society2025-10-01
MON-458 Crinecerfont Allows for More Physiologic Glucocorticoid Dosing Regimens in Patients With Classic Congenital Adrenal Hyperplasia: Results from the Phase 3 CAHtalyst™ Adult and CAHtalystTM Pediatric Studies
Journal of the Endocrine Society2025-10-01
7317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hyperplasia
Journal of the Endocrine Society2024-10-01
7152 CAHtalyst: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor (CRF1) Antagonist, In Adults With Classic Congenital Adrenal Hyperplasia
Journal of the Endocrine Society2024-10-01
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
New England Journal of Medicine2024-06-0241 citations
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
New England Journal of Medicine2024-06-0144 citations
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia
The Journal of Clinical Endocrinology & Metabolism2023-05-2223 citations